Publications by authors named "G Nunnari"
Critical Care Pharmacology of Antiretroviral Therapy in Adults.
Eur J Drug Metab Pharmacokinet
March 2025
The clinical pharmacology of antiretroviral therapy (ART) in critical care presents unique challenges due to the complex interplay between HIV infection, critical illness, and drug management. This comprehensive review examines the pharmacokinetic and pharmacodynamic considerations of antiretroviral drugs in critically ill patients, where altered absorption, distribution, metabolism, and excretion significantly impact drug effectiveness and safety. Critical illness can substantially modify drug pharmacokinetics through various mechanisms, including impaired gastrointestinal motility, fluid shifts, hypoalbuminemia, hepatic dysfunction, and altered renal function.
View Article and Find Full Text PDFViro-Immunological Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide among Women Living with HIV: A 96-Week Post-Switch Analysis from the Real-Life SHiNe-SHiC Cohort.
Biomedicines
October 2024
: Out of 39.9 million adults living with HIV in 2022, 20 million were women. Despite bearing a significant burden, women remain underrepresented in clinical trials, including those for antiretroviral treatments (ART).
View Article and Find Full Text PDFCervical cancer (CC) remains a prevalent malignancy and a significant global public health concern, primarily driven by persistent human papillomavirus (HPV) infections. The infectious nature of HPV underscores the preventability of CC through vaccination and screening programs. In addition to HPV, factors such as age, parity, smoking, hormonal contraceptives, and HIV co-infection elevate the risk of CC.
View Article and Find Full Text PDFArticle Synopsis
- Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is a fixed-dose combination therapy found to be effective for people living with HIV who switched from other treatments.
- A study involving 127 patients showed that virological suppression improved from 66.4% to 74.8% over 96 weeks, along with significant increases in CD4 and CD8 T cell counts and the CD4/CD8 ratio.
- The treatment was associated with lower levels of triglycerides and total cholesterol, indicating a better metabolic profile, although there was a notable increase in serum creatinine levels.
Article Synopsis
- The text discusses a case of bacteremia caused by non-O1/non-O139 strains (NOVC) of a Gram-negative bacterium, which can occasionally lead to severe infections in immunocompromised individuals.
- It focuses on a 71-year-old patient with advanced lung cancer who experienced fever, confusion, and asthenia due to NOVC bacteremia, confirmed through blood cultures.
- The patient responded well to treatment with antibiotics (ceftriaxone and ciprofloxacin), highlighting the need for quick diagnosis and targeted therapy in similar cases.